Mumps virus (MuV), a paramyxovirus containing a negative-sense nonsegmented RNA genome, is a human pathogen that causes an acute infection with symptoms ranging from parotitis to mild meningitis and severe encephalitis. Vaccination against mumps virus has been effective in reducing mumps cases. However, recently large outbreaks have occurred in vaccinated populations. There is no anti-MuV drug. Understanding replication of MuV may lead to novel antiviral strategies. MuV RNA-dependent RNA polymerase minimally consists of the phosphoprotein (P) and the large protein (L). The P protein is heavily phosphorylated. To investigate the roles of serine (S) and threonine (T) residues of P in viral RNA transcription and replication, P was subjected to mass spectrometry and mutational analysis. P, a 392-amino acid residue protein, has 64 S and T residues. We have found that mutating nine S/T residues significantly reduced and mutating residue T at 101 to A (T101A) significantly enhanced activity in a minigenome system. A recombinant virus containing the P-T101A mutation (rMuV-P-T101A) was recovered and analyzed. rMuV-P-T101A grew to higher titers and had increased protein expression at early time points. Together, these results suggest that phosphorylation of MuV-P-T101 plays a negative role in viral RNA synthesis. This is the first time that the P protein of a paramyxovirus has been systematically analyzed for S/T residues that are critical for viral RNA synthesis.
M
umps virus (MuV) is a human pathogen that causes acute parotitis and is highly neurotropic (1) . Invasion of the central nervous system is evident in almost half of all clinical cases, with asceptic meningitis occurring in approximately 10% of cases and encephalitis in less than 1% (1) . Even though the mumps vaccine has dramatically reduced disease incidence, large outbreaks have recently occurred in vaccinated populations (2, 3) . Over 5,700 mumps cases were reported in a 2006 outbreak that originated at a university in Iowa and spread to 10 other states (2) . A mumps outbreak occurred in New York and New Jersey in 2009 to 2010 where 88% of the patients had one dose of mumps vaccine and 75% of patients had two doses (3) . There is no antiviral drug for MuV infection. Understanding functions of viral proteins will aid development of antiviral strategies. In this study, a strain of MuV from a recent outbreak in Iowa in 2006 (4), MuV Iowa/US/06 (referred to here as MuV), was used to examine the role of phosphorylation of the MuV phosphoprotein (P) in virus transcription and replication.
MuV is a member of the family Paramyxoviridae and has a nonsegmented, negative-stranded RNA genome of 15,384 nucleotides (1) . The RNA genome of MuV contains a series of tandemly linked genes separated by nontranscribed sequences in the order 3=-NP-V/P-M-F-SH-HN-L-5=. Synthesis of all viral mRNAs initiates at the 3= end sequence, termed the leader sequence, where the viral RNA-dependent RNA polymerase (RNAP) (vRdRp) transcribes the viral RNA genome (vRNA) into mRNAs, containing a 5= cap structure and 3= poly(A) tail, in a sequential manner. To replicate vRNA (the negative-sense viral RNA), an anti-genome sense RNA (cRNA or positive-sense anti-genomic RNA) is first replicated starting at the 3= leader sequence and then the cRNA is replicated into the vRNA by vRdRp starting at the 5= trailer sequence (5) . The functional template for viral RNA synthesis (viral mRNA transcription and viral RNA replication) of MuV, like other nonsegmented, negative-sense RNA viruses, is contained in the helical nucleocapsid, i.e., the viral genomic RNA encapsidated by the nucleoprotein (NP) (reviewed in reference 5). The vRdRp of MuV minimally consists of two proteins, the phosphoprotein (P) and the large (L) polymerase protein (6) . The L protein has enzymatic activities capable of initiation, elongation, and termination of RNA synthesis, and the L protein adds the 5= cap and 3= poly(A) sequence to transcribed viral mRNA (5) . P is an essential cofactor for the polymerase. The P protein does not have intrinsic enzymatic activity, but it has numerous functions in virus transcription and replication (5) . It enables binding of the P-L complex to the nucleocapsid template and prohibits self-assembly of nascent NP protein (7) .
To study the functions of NP, P, and L of paramyxoviruses in the absence of viral infection, minigenome systems are often used. The system contains NP, P, and L but lacks all other viral proteins, and the viral genome is substituted by an RNA with a reporter gene that is flanked by the 3= leader sequence and the 5= trailer sequence (8, 9) . In this study, mass spectrometry analysis and a MuV minigenome system were used to screen for S/T amino acid residues of the P protein that are phosphorylated and critical for virus transcription and replication. Furthermore, the putative critical residues were incorporated into a recombinant MuV and analyzed.
MATERIALS AND METHODS
Plasmids and cells. Plasmids used in this work were constructed using standard molecular cloning techniques. Construction details and sequence files of the plasmids are available upon request. MuV NP, P, and L genes were cloned into the pCAGGS expression vector (10) . A plasmid containing firefly luciferase (pFF-Luc) and the MuV minigenome plasmid (BH526/pMG-RLuc), containing Renilla and driven by the T7 promoter, were used in the MuV minigenome assays. Mutations in the P protein were incorporated into the full-length MuV genome (MuV Iowa/US/06 ) as described before (4) .
293T cells were maintained in Dulbecco's modified Eagle medium (DMEM) with 5% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) (Mediatech Inc., Manassas, VA). Vero and HeLa cells were maintained in DMEM supplemented with 10% FBS and 1% P/S. BSRT7 cells were maintained in DMEM supplemented with 10% FBS, 1% P/S, 10% tryptose phosphate broth (TPB), and 400 g/ml G418 sulfate antibiotic (Mediatech Inc.). All cell lines were incubated at 37°C with 5% CO 2 and passed at an appropriate dilution 1 day prior to use to achieve 80% to 90% confluence upon transfection or infection.
Transfections, infections, and virus rescue. Cells were transfected using JetPRIME (Polyplus Transfection Inc., New York, NY) following the manufacturer's protocols. For virus infections, cells were inoculated with viruses at a multiplicity of infection (MOI) of 0.5, 0.1, or 0.01 in DMEM-1% bovine serum albumin (BSA) and incubated at 37°C with 5% CO 2 for 1 to 2 h. The inocula were then replaced with DMEM supplemented with 2% FBS and 1% P/S.
To rescue an infectious virus, a plasmid containing the full-length genome (5 g), along with plasmids pCAGGS-L (2 g), pCAGGS-NP (100 ng), and pCAGGS-P (320 ng), was transfected into BSRT7 cells. Three days later, transfected BSRT7 cells were mixed with Vero cells at a 1:5 dilution. Four days later, media were transferred to fresh Vero cell monolayers and propagated further. When syncytium formation was observed, media were collected and used for plaque assays in Vero cells as previously described (11) . Single plaques were selected and further amplified in Vero cells. The genome of the rescued virus was confirmed by sequencing. Total RNA was extracted from infected cells using an RNeasy minikit (Qiagen, Waltham, MA) and reverse transcribed into cDNA using Super Script III reverse transcriptase (Invitrogen, Frederick, MD) with random primers (Promega, Madison, WI). Synthesized cDNA served as the templates for PCR using MuV genome-specific primers and Taq polymerase (Invitrogen). Primers (15 sets) were designed to divide the genome into overlapping fragments, and the primers were used for the subsequent sequencing of the PCR products, as previously described (4) . Primer sequences are available upon request.
Mass spectrometry analysis. To determine the phosphorylated residues within the P protein of MuV-infected cells, liquid chromatographytandem mass spectrometry (LC-MS/MS) was performed as previously described (12) . Vero cells in 10-cm-diameter plates were mock or MuV infected at an MOI of 0.5. At 24 h postinfection (hpi), the cells were lysed with whole-cell extraction buffer (WCEB) (50 mM Tris-HCl [pH 8.0], 280 mM NaCl, 0.5% NP-40, 0.2 mM EDTA, 2 mM EGTA, and 10% glycerol) with a mixture of protease inhibitors as previously described (13) . Lysates were incubated with monoclonal anti-MuV-P antibody (4) [DTT] ), heated at 95°C for 5 min, and resolved using 10% SDS-polyacrylamide gel electrophoresis (PAGE). The gel was stained with Coomassie blue in a solution of 45% methanol and 10% acetic acid. After destaining with a solution containing 45% methanol and 10% acetic acid, the major and minor phosphorylated P bands became visible and were excised separately. The bands were digested with trypsin, enriched using TiO 2 , and analyzed by LC-MS/MS (using the Waters Q-Tof Ultima mass spectrometer at the W.M. Keck Foundation Biotechnology Resource Laboratory, Yale University). The MS/MS spectra were searched against the NCBI database using the automated Mascot algorithm to identify peptides with possible phosphorylation residues of tyrosin (Tyr), threonine (Thr), and serine (Ser).
MuV minigenome system and dual-luciferase assay. BSRT7 cells in 24-well plates were transfected with pCAGGS-NP (25 ng), pCAGGS-L (500 ng), pMG-RLuc (100 ng), pFF-Luc (1 ng), and various amounts (0, 20, 40, 80, 160, or 320 ng) of pCAGGS-P or pCAGGS-P mutant. Empty pCAGGS vector was used to normalize the amount of transfected DNA per sample. After 48 h, cells were lysed in 100 l passive lysis buffer (Promega, Madison, WI) and vigorously mixed for 20 min to permit full lysis. Clear lysate (40 l) from each well was used to carry out the dual-luciferase assay according to the manufacturer's protocol (Promega), and light intensity was detected using a GloMax 96 Microplate Luminometer (Promega). Relative luciferase activity was defined as the ratio of Renilla luciferase (R-Luc) to firefly luciferase (FF-Luc) activity. Six replicates of each sample were used to compare the peak activity of each P mutant to that of wild-type P. Aliquots of the minigenome system cell lysates were used for Western blot analysis to detect NP and P protein expression.
Immunoblotting. Cell lysate aliquots from the dual-luciferase assay were mixed with one-half volume of 3ϫ SDS loading buffer and heated at 95°C for 5 min. Samples were resolved in 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (GE Healthcare, Piscataway, NJ). Immunoblotting using monoclonal MuV protein-specific antibodies was performed as previously described (4). The membrane was incubated with mouse anti-MuV-NP antibody (1:2,000 dilution) and mouse antiMuV-P antibody (1:1,000 dilution), followed by incubation with Cy3-conjugated goat anti-mouse IgG secondary antibody (1:2,500 dilution) (Jackson ImmunoResearch, West Grove, PA), and scanned using a Typhoon 9700 imager (GE Healthcare Life Sciences, Piscataway, NJ).
To compare the viral protein expression levels in infected cells, Vero cells were mock infected or infected with recombinant MuV (rMuV) or rMuV-P-T101A at an MOI of 0.01. At 12, 24, 48, 72 , and 96 h postinfection (hpi), cells were lysed with WCEB and cell debris was removed. Lysates were mixed with 3ϫ SDS loading buffer, heated, and resolved using a 10% SDS-PAGE gel as described above. Immunoblotting was performed with primary antibodies and with mouse anti-MuV-NP and -P antibodies as described above as well as with rabbit anti-actin antibody at a 1:1,000 dilution (Sigma-Aldrich, St. Louis, MO), followed by Cy3-conjugated goat anti-mouse IgG secondary antibody and Cy5-conjugated goat antirabbit IgG secondary antibody at 1:2,500 dilutions (Jackson ImmunoResearch).
IP. To detect phosphorylation of P, HeLa cells were transfected with 2 g of pCAGGS-P or pCAGGS-P mutant or infected with MuV or rMuV-P-T101A at an MOI of 0.1. At 18 hpi, the cells were starved with DMEM lacking cysteine-methionine and then labeled with 72.7 Ci/ml 35 SEasyTag Express35S Protein Labeling (PerkinElmer, Waltham, MA) for 4 h or starved with DMEM lacking sodium phosphate and then labeled with 100 Ci [ 33 P]Radionuclide Orthophosphoric acid (PerkinElmer, Waltham, MA) and 100 nM okadaic acid (Sigma-Aldrich) for 8 h. The cells were then lysed with WCEB, and the lysate was subjected to immunoprecipitation (IP) using recombinant protein G-Sepharose 4B conjugate and anti-MuV-P antibody. The immunoprecipitated products were washed and resolved as described above. Phosphorylation of the P protein of 4 individual experiments was calculated by densitometry analysis of the total P 33 P/ 35 S ratio using ImageQuant TL software (GE Healthcare Life Sciences).
To detect tetramer formation of P and P mutants, Vero cells in 6-cmdiameter plates were mock infected or infected with rMuV or rMuV-P-T101A at an MOI of 0.5. At 24 hpi, the cells were starved with DMEM lacking cysteine-methionine and then labeled with 72.7 Ci/ml 35 SEasyTag Express35S Protein Labeling (PerkinElmer) for 4 h. The labeled cells were incubated with dimethyl sulfoxide (DMSO) or 1 mM disuccinimidyltartarate (DSP) (Pierce, Rockford, IL) in PBS-0.5% NP-40 to cross-link the disulfide bonds as previously described (14) and incubated for 2 h at 4°C. The cells were lysed using protein G-Sepharose 4B conjugate (Invitrogen) and anti-MuV-P. Samples were washed and then mixed with a half-volume of 3ϫ SDS loading buffer. The immunoprecipitated products were washed with WCEB and resolved using 10% SDS-PAGE. The gel was fixed and dried, and the proteins were visualized using a Typhoon 9700 imager (GE Healthcare).
To study the interaction of NP and L with P and P mutants, Vero cells in 6-cm-diameter plates were mock infected or infected with MuV or rMuV-P-T101A at an MOI of 0.5. At 24 hpi, the cells were starved and labeled as described above. The cells were then lysed with WCEB and the lysate was immunoprecipitated using protein G-Sepharose 4B conjugate (Invitrogen) and half of the lysate with anti-MuV-P and half with antiMuV-NP antibodies. The IP products were washed with WCEB and resolved using 10% SDS-PAGE. The gel was fixed (20% methanol, 7% acetic acid) and dried, and the proteins were visualized using a Typhoon 9700 imager (GE Healthcare).
Multistep growth curve. Vero cells in 6-cm-diameter plates were infected with MuV or rMuV-P-T101A at an MOI of 0.01. Media were collected at 12, 24, 48, 72, and 96 hpi and supplemented with 1% BSA and then stored at Ϫ80°C. Virus titers were determined in Vero cells by plaque assays and completed in triplicate as previously described (11) .
Flow cytometry. Vero cells in 6-well plates were infected with MuV or rMuV-P-T101A at an MOI of 0.1. Trypsonized cells of 4 individual replicates were harvested and combined with floating cells in the media at 12, 24, 48, and 72 hpi, fixed in PBS with 1% formaldehyde, and stored at 4°C. Cells were permeabilized in PBS with 5% FBS and 0.5% saponin and stained with anti-MuV-NP antibody at a 1:200 dilution, followed by Rphycoerythrin (PE)-labeled goat anti-mouse IgG secondary antibody at a 1:200 dilution (KPL, Gaithersburg, MD). Flow cytometry was completed using a LSRII flow cytometer (BD Biosciences, San Jose, CA) and analyzed using BD FACSDiva v6 software (BD Biosciences). The mean fluorescence intensity of NP was calculated for infected cells.
RT PCR. Vero cells in 6-well plates were infected with MuV or rMuV-P-T101A at an MOI of 0.01. Total RNA was extracted at 0, 2, 4, 8, 12, 16, and 20 hpi using an RNeasy minikit (Qiagen). cDNA was generated using reverse transcription with Super Script III reverse transcriptase (Invitrogen). Oligo(dT) 15 primers (Promega) were used to synthesize cDNA for viral mRNA, and gene-specific primers flanking the negative-sense genomic MuV-F gene were used for synthesizing cDNA for genomic RNA. Synthesized cDNAs served as the templates for real-time PCR (RT-PCR) in triplicate using a MuV-F-specific FAM-tagged probe (Applied Biosystems, South San Francisco, CA) and TaqMan Gene Expression Master Mix (Applied Biosystems), according to the manufacturer's protocol. Real-time PCR was completed using a StepOnePlus RT PCR system (AB Biosciences, Foster City, CA). Threshold cycle (C T ) values were normalized to input RNA (defined as the genomic RNA for the corresponding virus when the inoculum was removed at 0 hpi). The products were resolved in SDS-PAGE and stained with Commassie blue. Both the major (P 1 ) and minor (P 2 ) phosphorylated P bands were excised and processed for mass spectrometry analysis. The excised proteins were digested with trypsin, enriched using TiO 2 , and analyzed by LC-MS/MS. (C) Schematic of LC-MS/MS coverage of the major phosphorylated MuV P protein (P 1 ). All serine and threonine residues are boxed, and underlined residues represent the detected peptides. MS achieved 73.9% P coverage. S/T residues highlighted in black represent detected phosphorylated residues, which included T147, T165, S188, and T265. (D) Schematic of LC-MS/MS coverage of the minor phosphorylated MuV P protein (P 2 ). MS achieved 88.5% P coverage. S/T residues highlighted in black represent detected phosphorylated residues, which included T10, T16, T39, S69, T91, T150, T165, S188, T250, S257, T258, T282, S374, and T375.
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA). Student's t test was used to calculate P values.
RESULTS

Mass spectrometry analysis of P.
To determine the phosphorylation status of the P protein of the MuV Iowa/US/06 strain (referred to here as MuV), Vero cells were infected with MuV, radioactively labeled with [
35 S]Met or [ 33 P]phosphate, and then immunoprecipitated with monoclonal anti-MuV-P antibody. The immunoprecipitated products were resolved using SDS-PAGE. Consistent with previous observations, there were two bands distinguished for the P protein in the 35 S-labeled lane: a slower-migrating minor band (P 1 ) and a faster-migrating major band (P 2 ) (Fig. 1A) . It had been speculated that the slower-migrating band was P with increased phosphorylation. When the major 35 S-labeled P 2 was labeled with 33 P, the weaker 35 S-labeled P 1 band had stronger 33 P labeling, indicating that P 1 was the major phosphorylated product of P (Fig. 1A) . To determine phosphorylation sites within the MuV P protein, the P protein from MuV-infected cells was purified using a monoclonal anti-MuV-P antibody (Fig. 1B ). Both the P 1 and P 2 bands were excised separately from the SDS-PAGE gel and then subjected to trypsin digestion and TiO 2 enrichment and analyzed by LC-MS/MS, as previously described (12) . The coverage of the mass spectrometry analysis for the P 1 band was 73.9% with 4 predicted phosphorylated residues (Fig. 1C) , and the coverage of the mass spectrometry analysis for the P 2 band was 88.5% with 14 predicted phosphorylated residues (Fig. 1D) . Upon morerigorous statistical analysis (peptides receiving an expectation/ random probability score greater than 5% were excluded), the coverages and putative sites for the P 1 and P 2 bands were reduced to 61.6% and 76.4% with 0 and 2 phosphorylation sites, respectively. Only residues S69 and T165 were considered phosphorylated. A summary of the results is shown in Table 1 , where the higher-stringency phosphorylation data are provided using two "plus" symbols (ϩϩ).
Effects of mutating S69 and T165 to alanine in the minigenome system. To study the role of P in viral transcription and replication, a minigenome system for MuV is desirable. Our laboratory has previously developed a minigenome system, free of vaccinia virus, for parainfluenza virus 5 (PIV5) (8) , which is closely related to MuV. By the use of a similar approach, a plasmid containing a renilla luciferase gene flanked by the MuV leader and trailer sequences under the control of a T7 RNAP promoter, along with plasmids expressing the proteins NP, P, and L, was transfected into BSRT7 cells. To study whether phosphorylation of the P protein affects MuV transcription and/or replication, the S69 and T165 putative phosphorylated residues that were detected with LC-MS/MS were mutated to alanine and the mutants were then tested in the minigenome system ( Fig. 2A and B) . Because the ratio of NP to P is critical for the minigenome activity, a range of concentrations of the P plasmid was used to obtain the maximal minigenome activity. Expression levels of P and NP were determined using immunoblotting (Fig. 2C) . Mutating T165 and S69 to alanine resulted in peak luciferase activities similar to those seen with wild-type P ( Fig. 2A and B) , indicating that phosphorylation of these residues did not play a role in MuV transcription and/or replication in the minigenome system.
A systematic mutational analysis of P. To identify potential serine and threonine phosphorylation sites within P that are critical for viral RNA synthesis, all serine and threonine residues were mutated to alanine and all mutants were tested in the minigenome system. Clusters of mutations that affected the minigenome activity (P Ͻ 0.01) were then mutated individually and the mutants with a single amino acid changes were tested. This screen identified substitutions that reduced minigenome activity (T10A, T250A, S257A, T258A, T261A, T262A, T265A, T350A, and a Summary of minigenome activity of MuV P protein mutants. All serine and threonine residues of the MuV P protein were mutated to alanine. The effects of the mutations were examined in the MuV minigenome system. Peak luciferase activities of P protein mutants relative to wild-type P protein were calculated and are shown. Clusters of significant residues were individually mutated and tested again. Standard errors of the means (SEM) of data from 6 replicates are provided. P values were calculated using Student's t test, and critical residues are highlighted in boldface. MS-detected phosphorylated residues are symbolized by ϩ, and residues in peptides receiving an expectation/random probability score of less than 5% are symbolized by ϩϩ.
T354A) and one substitution that enhanced minigenome activity (T101A), indicating that these residues were important for transcription and/or replication in the minigenome system. Table 1 summarizes the minigenome data for all serine and threonine residues in P, with the critical residues highlighted in boldface. Expression levels of P mutants were determined using immunoblotting, and similar expression levels of P were detected in wildtype and mutant P-transfected cells (data not shown), indicating that the mutations did not affect expression of P. Minigenome results and immunoblotting analysis for T10A, a representative mutation that negatively affected the minigenome activity, and T101A, the mutation that positively affected the minigenome activity, are provided ( Fig. 3A and B) . Using the ViPR database, sequence comparison of 59 different MuV isolates showed that nine residues (T10, T250, S257, T258, T261, T262, T265, and Table 1 were phosphorylated, plasmids expressing mutant T10A and T101A were transfected into HeLa cells and the cells were radioactively labeled with 35 S or 33 P and then immunoprecipitated with monoclonal anti-MuV-P antibody as described above. Interestingly, the P protein band patterns in transfected cells differed from those in infected cells (Fig. 4A) . Because of this, we were concerned that using transfected cells for analyzing P phosphorylation might generate misleading results. We decided to incorporate the mutations into the genome of MuV amounts of P or P-T165A were transfected together with other plasmids as described in Materials and Methods. The negative control (NC) contained no transfected P. Renilla luciferase was the reporter gene in the minigenome, and Firefly luciferase expression was used as a transfection control. The minigenome activity was measured and normalized as the ratio of Renilla luciferase activity to firefly luciferase activity (relative luciferase activity). (B) Minigenome activity of P-S69A. P values were calculated using Student's t test. Error bars represent the standard errors of the means (SEM) of data from 6 replicates. *, P Ͻ 0.001. (C) Immunoblotting was performed to detect the expression levels of NP and P, P-T165A, or P-S69A.
T350) were conserved (data not shown). The only variance was found at T354 for two mumps virus isolates (Mumps_Virus_ ODATE-3 [GenBank accession no. AB600942] and Mumps_ virus_Y213 [GenBank accession no. AB576764]).
Reduced P phosphorylation in rMuV-P-T101A-infected cells. To determine if the S and T residues identified in
FIG 3
Identification of the S/T residues that were critical for RNA synthesis using the MuV minigenome system. Minigenome activity of P-T10A (A) and P-T101A (B) is shown. P values were calculated using Student's t test. Error bars represent the SEM of data from 6 replicates. *, P Ͻ 0.001. Western blotting was performed to detect the expression levels of NP and P, P-T10A, and P-T101A. and tried to recover infectious virus with the mutations. We have been successful in incorporating the mutations into the genome of MuV cDNA. Using a reverse genetics system we developed, a recombinant virus containing the P-T101A mutation (rMuV-P-T101A) was recovered and confirmed by sequencing (Fig. 4B) . We attempted to rescue infectious virus containing P-T10A 11 times. However, we were unsuccessful even though a recombinant MuV that expresses GFP was recovered alongside 9 of these attempts. We speculate that rMuV-P-T10A mutation likely cause defects in virus growth.
To determine the impact of the T101A mutation on the phosphorylation status of P, HeLa cells were mock infected or infected with MuV or rMuV-P-T101A at an MOI of 0.01. The infected cells were radioactively labeled with 35 S or 33 P, and cell lysates were immunoprecipitated with monoclonal anti-MuV-P. As shown in Fig. 4C , P protein phosphorylation of rMuV-P-T101A was significantly reduced by about 35% compared to MuV phosphorylation (Fig. 4D) , indicating that T101 was phosphorylated in infected cells. The partial reduction of phosphorylation is consistent with the observation that P has multiple phosphorylation sites.
rMuV-P-T101A grew to higher titers than MuV in tissue culture cells. To examine growth rates of rMuV-P-T101A in cells, Vero cells were infected with MuV or rMuV-P-T101A at an MOI of 0.01 and media from infected cells were collected at different intervals until 96 h postinfection (hpi). Titers of virus in the media were determined using a plaque assay. rMuV-P-T101A grew to a higher titer than MuV at 24 hpi and maintained its higher titer at all time points (Fig. 5A) . Similar results were obtained in HeLa cells (Fig. 5B) .
Viral protein expression levels in rMuV-P-T101A-infected cells. To examine viral protein expression levels in rMuV-P-T101A-infected cells, Vero cells were infected. Lysates from infected cells were collected at various time points and subjected to immunoblotting with monoclonal anti-MuV-NP. At 24 hpi, the band intensity of NP from rMuV-P-T101A-infected cells was greater than that from rMuV-infected cells (Fig. 6A) . However, no significant difference in band intensity was observed at later time points (Fig. 6A) .
Enhanced viral protein expression in rMuV-P-T101A-infected cells shortly after infection was confirmed by flow cytometry. At 24 hpi, rMuV-P-T101A-infected cells had a greater mean fluorescence intensity (MFI) than MuV-infected cells (Fig. 6B ) and no significant difference was observed at later time points, consistent with the results from immunoblotting transfected with pCAGGS-P or pCAGGs-P mutants or infected with MuV and labeled with 35 S or 33 P. Cell lysates were immunoprecipitated with monoclonal anti-MuV-P antibody and resolved on a 10% SDS-PAGE gel. (B) Sequence confirmation of rMuV-P-T101A. The genome of rMuV-P-T101A was sequenced, and the region that contained the mutation is shown. (C) Phosphorylation of P in rMuV-P-T101A-infected cells. Mock-, MuV-, and rMuV-P-T101A-infected HeLa cells were labeled with 35 S or 33 P. Cell lysates were immunoprecipitated with monoclonal anti-MuV-P and resolved on a 10% SDS-PAGE gel. (D) Relative phosphorylation level of P in infected cells. The relative level was calculated as the ratio of phosphorylated protein ( 33 P-labeled P) to total protein ( 35 S-labeled P) and standardized to that of MuV. P values were calculated using Student's t test. Error bars represent the SEM of data from 4 individual experiments. (Fig. 6A) . The findings that mutating P-T101 to A resulted in a mutant with increased minigenome activity and in a recombinant virus with enhanced growth at early stages after infection indicate that phosphorylation of T101 negatively regulates viral RNA transcription and replication.
rMuV-P-T101A had a higher level of viral RNA transcription than wild-type MuV. To further investigate the mechanism of accelerated viral protein expression in rMuV-P-T101A-infected cells, real-time PCR was used to compare the levels of viral mRNA and viral genomic RNA in Vero cells. The cells were infected with MuV or rMuV-P-T101A at an MOI of 0.01, and total RNA was purified from infected cells at 2, 4, 8, 12, 16 , and 20 hpi. Interestingly, more viral mRNAs were detected in rMuV-P-T101A-infected cells at earlier time points (4 and 8 hpi) (Fig. 7A ) whereas significantly more viral genomes were produced by MuV at 8 and 16 hpi (Fig. 7B) . Overall, there was an increased viral mRNA-togenome ratio in rMuV-P-T101A-infected cells compared to MuV-infected cells (Fig. 7C) . This indicates that the T101A mutation enhanced viral mRNA transcription, suggesting that phosphorylation at this residue negatively regulates viral mRNA transcription in infected cells.
Mutation of a critical P residue did not affect P oligomerization or NP-P-L complex interactions. P is known to form homooligomers and to interact with NP and L. To investigate the mechanism for the effect of T101-to-A mutation, the ability of P-T101A to form homo-oligomers was examined using dithiobis succinimidyl propionate (DSP), a cross-linking agent. The mutant P protein of rMuV-P-T101A-infected Vero cells formed dimers and tetramers similar to those formed by the wild-type P protein of rMuV in infected cells (Fig. 8A) , suggesting that the mutation did not affect oligomerization of P.
NP-P-L complex interactions were examined using coimmunoprecipitation of infected Vero cells. The P, NP, and L interactions seen with MuV-infected cells and rMuV-P-T101A-infected cells were similar (Fig. 8B) , suggesting that the P-T101 residue did not play a role in NP and L interaction.
DISCUSSION
In this study, we performed mass spectrometry, as well as a systematic mutational analysis, to identify S and T residues of the P protein that are critical for MuV transcription and replication. To the best of our knowledge, this is the most comprehensive study that has been performed for a paramyxovirus protein to investigate the roles of S/T residues and their potential phosphorylation in viral RNA synthesis. Interestingly, there is little overlap between MS-identified S/T phosphorylation sites and the S/T residues identified by mutational analysis. While MS can directly detect phosphorylation of S/T residues, this method is limited by many factors, such as the amount of sample available for analysis, time of sample collection (phosphorylation of a site can be temporally regulated), and percentage of total protein that is phosphorylated at the time of sample collection (only a small percentage of a given S/T residue may be phosphorylated at the time of sample collection). Mutational analysis can overcome these issues. However, the results generated through mutational analysis are circumstantial with respect to determining whether these S/T residues are phosphorylated. Thus, mutational analysis using a minigenome system is likely to identify critical S/T residues for viral RNA synthesis, but whether they are indeed phosphorylated and whether their phosphorylation plays a critical role in viral RNA synthesis need further investigation. Using a reverse genetics system, we incorporated a P-T101A mutation into the MuV genome and analyzed the mutant virus. The findings that (i) mutating T101 of the P protein to A resulted in a virus that resembled the phenotype of T101A in the minigenome and (ii) the phosphorylation level of P of the mutant virus was reduced compared to the wild-type P level indicate that T101 is likely phosphorylated and that its phosphorylation is important for regulating viral RNA synthesis. The observation that 9 of 10 S/T residues identified by the mutational analysis are conserved among 59 different isolates of MuV indicates that these residues play a critical role in the functionalities of P. Further analysis of these S/T residues using a similar approach with a reverse genetics system is under way.
To investigate the mechanism for the enhanced viral protein expression in rMuV-P-T101A-infected cells at an early stage after initial infection, viral mRNA synthesis and genome replication were examined. It was found that the T101A mutation led to higher transcription levels of viral mRNA. The NP, P, and L proteins are packaged in the virion of negative-sense RNA viruses. Upon infection, these proteins transcribe viral genome to generate the viral mRNAs to produce more viral proteins. Accumulation of the soluble NP-P complex is thought to trigger the switch from RNA transcription to genome replication (15) (16) (17) . However, the fact that P and mutant T101A interacted with NP at similar levels indicates that the mutant did not exert its impact on viral mRNA synthesis through its interaction with NP. That the ability of the mutant P to oligomerize as well as to interact with L in infected cells remained the same as that of wild-type P suggests that the mutation at T101 likely acts through a host factor. Identification of this host factor will lead to a better understanding of the mechanism of T101A's regulation of viral mRNA synthesis. To measure viral mRNA levels, oligo(dT) primers and a MuV-F-specific 6-carboxyfluorescein (FAM)-tagged probe were used for real-time PCR. Genome levels of MuV or rMuV-P-T101A at 0 hpi were used as the baseline for normalization. (B) Genome replication of MuV and rMuV-P-T101A in Vero cells at an MOI of 0.01. To measure genomic RNA levels, gene-specific primers flanking the negative-sense genomic MuV-F gene and a MuV-F-specific FAM-tagged probe were used for real-time PCR. Genome levels at 0 hpi for each virus were used as a baseline for normalization. (C) Relative viral mRNA (vmRNA) levels per genome at each time point were calculated for MuV-or rMuV-P-T101A-infected Vero cells at an MOI of 0.01. P values were calculated using Student's t test. *, P Ͻ 0.05; **, P Ͻ 0.01. Error bars represent the SEM of data from 3 replicates. While mumps vaccines have been effective in reducing cases of mumps, recent outbreaks in vaccinated populations raise concerns about vaccination programs. The current mumps vaccine was developed based on a genotype A strain in the 1960s and has been used ever since. A new mumps vaccine that matches circulating strains (for instance, genotype G in the U.S. outbreaks) may be ideal. We have used a reverse genetics system to develop novel mumps vaccine candidates based on genotype G by introducing specific mutations in the genome of MuV, such as deletion of SH and V (4, 11) . One challenge for generating a vaccine is to obtain a virus that grows well in tissue culture cells for vaccine production purposes and is also attenuated in vivo. Incorporating the mutation at P-T101 into vaccine candidates may increase vaccine yields during production.
The importance of P protein phosphorylation in paramyxovirus transcription and replication has been studied in many paramyxoviruses, and it has been shown to play a role in regulating viral mRNA synthesis (14, 15, 16, 17, 18) . It is commonly believed that phosphorylation of the P proteins is carried out by host kinases (18) . The host kinases CKII, protein kinase C-(PKC-), AKT, and PLK1 have been identified so far as the main host kinases that phosphorylate paramyxovirus P proteins. CKII is thought to phosphorylate the P proteins of respiratory syncytial virus (RSV) (19, 20) and measles virus (21) . PKC-is reported to phosphorylate the P proteins of human parainfluenza virus 3 (HPIV3) (22) and Sendai virus (23) . The P protein of canine distemper virus is phosphorylated by both PKC-and CKII (24) . AKT phosphorylates the P protein of PIV5 to upregulate its gene expression whereas PLK1's phosphorylation of P of PIV5 downregulates its gene expression. It has been proposed to target host kinases that are critical for viral RNA synthesis as an antiviral strategy for these paramyxoviruses (25) . The identification of S/T residues and phosphorylation sites within MuV P will aid in the identification of host kinases that are important for MuV replication, which will lead to novel targets for anti-MuV drug development.
